Global Domperidone Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Oral Solution, Tablets, and Injection), By Route of Administration (Oral and Intravenous), By Indications (Nausea and Vomiting, Functional Dyspepsia, and Gastric Motility Disorders), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Domperidone Market Insights Forecasts to 2033

• The Global Domperidone Market Size Was Estimated at USD 1.35 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 3.85% from 2023 to 2033
• The Worldwide Domperidone Market Size is Expected to Reach USD 1.97 Billion By 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

The Global Domperidone Market Size is Predicted to Exceed USD 1.97 Billion by 2033, Growing at a CAGR of 3.85% from 2023 to 2033.

Market Overview

The domperidone market is categorized under the pharmaceutical sector that deals with the development, production, and commercialization of the domperidone medications that are used in the treatment of gastrointestinal disorders. Domperidone is a medication that helps prevent sickness and is used to address symptoms like heartburn, indigestion, vomiting, and nausea. It acts on the area of the brain that regulates vomiting and boosts the activity of the stomach and intestines, thereby easing the passage of food. Domperidone, a dopamine receptor antagonist, is utilized as a peristaltic stimulant and anti-emetic agent for conditions such as dyspepsia, indigestion, epigastric pain, nausea, and vomiting. Additionally, it functions as an antagonist of dopamine receptors. It is also used in the management of the nausea and vomiting caused by other drugs used in the treatment of Parkinson’s disease. Domperidone is used in combination with other drugs, such as antacids like pantoprazole, which drives the market growth. The marketed products of domperidone are Domwell-10 tablets, DoponCare syrup, etc.

The increasing prevalence of postoperative nausea and vomiting and pregnancy-associated nausea and vomiting accelerates the need for anti-emetic medications, which results in the growth of the domperidone market. For instance, postoperative nausea and vomiting (PONV) is a common issue in various surgeries, with prevalence rates of 31.4% and 16.8%, with higher rates during the first 24 hours in European countries.

The market for domperidone is growing as a result of the growing incidence of gastrointestinal disorders and nausea-related conditions, heightened awareness of digestive health, and improved access to healthcare services. Advancements in medications that are formulated and delivered are enhancing the effectiveness of domperidone and improving patient compliance. The rising utilization in developing countries is additionally propelling market growth.

Report Coverage

This research report categorizes the global domperidone market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global domperidone market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global domperidone market.

Driving Factors:

The domperidone market is experiencing growth due to the increasing prevalence of gastrointestinal disorders and the awareness of their benefits. Advances in diagnostic technologies are playing a crucial role in identifying these conditions early, increasing demand for therapeutic agents like domperidone. The drug is also being used in lactation induction, particularly in regions with high birth rates and breastfeeding-promoting policies. The pharmaceutical industry is investing in developing new formulations and delivery methods, improving patient compliance and outcomes. The emergence of online pharmacies and increased accessibility of medications further support market growth.
The domperidone market presents opportunities for expansion beyond its current uses, such as managing chemotherapy-induced nausea and vomiting and other chronic conditions. The successful development of new indications could significantly boost market potential. The growing demand for personalized medicine and targeted therapies is another opportunity, with advances in pharmacogenomics and precision medicine enabling healthcare providers to tailor treatments to individual patient needs. The increasing adoption of telemedicine and digital health platforms further enhances the market potential for domperidone.

Restraining Factors

The side effects associated with repeated use of domperidone, lack of awareness of the treatment for the emesis, use of natural ingredients and home remedies, stringent regulatory framework, and availability of alternative medications may impede the market growth.

Market Segmentation

The global domperidone market share is classified into dosage form, route of administration, indications, and distribution channel.

• The tablets segment dominated the global domperidone market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the dosage form, the global domperidone market is categorized into oral solution, tablets, and injection. Among these, the tablets segment dominated the global domperidone market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is attributed to the enhanced chemical and physical stability, ease of administration, patient-convenience, better bioavailability, reduced risk of microbial contamination due to the absence of water, rapid dissolution rate, better disintegration rate, enhanced biopharmaceutical properties, and faster onset of action.

• The oral segment held the largest market share in 2023 and is expected to grow at a CAGR of 3.74% throughout the projected timeframe.

Based on the route of administration, the global domperidone market is categorized into oral and intravenous. Among these, the oral segment held the largest market share in 2023 and is expected to grow at a CAGR of 3.74% throughout the projected timeframe. The segment growth is attributed to the cost effectiveness of the oral medications, the safest route of administration without any invasions, patient compliance, targeted drug delivery medications, and ease of ingestion.

• The gastric motility disorders segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the indications, the global domperidone market is categorized into nausea and vomiting, functional dyspepsia, and gastric motility disorders. Among these, the gastric motility disorders segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The growth of the segment is driven by the increasing prevalence of gastroparesis, sedentary lifestyles, and rising cases of gastroesophageal reflux disease and achalasia.

• The hospital pharmacies segment dominated the global domperidone market in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global domperidone market is categorized into retail pharmacies, online pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment dominated the global domperidone market in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The sector growth is ascribed to the rising admissions for inpatient services, availability of the wide stock of medication, health care policies facilities such as Mediclaim, and other government schemes.

Regional Segment Analysis of the Global Domperidone Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global domperidone market over the predicted timeframe.

North America is anticipated to hold the largest share of the global domperidone market over the predicted timeframe. In North America, the United States is leading in the domperidone market is primarily controlled by major pharmaceutical firms and current clinical studies, fueled by an increase in gastrointestinal disorder cases and a heightened focus on personalized medicine. In areas where the birth rate is high, there has been growing interest in using medication to induce lactation. Pharmaceutical companies are investing in research aimed at developing innovative formulations like extended-release tablets and oral suspensions to enhance patient compliance and broaden the applications of medications. Competition fuels innovation and pricing tactics, while the incorporation of technology into healthcare, like telemedicine and e-pharmacies, enhances the accessibility of domperidone for patients in North America. These factors are expected to lead to a steady growth of the market.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. The demand for drugs such as domperidone in the region, especially in India and China, is growing because of the large population, increasing healthcare spending, and advancements in diagnostic technologies. The demand for domperidone is driven by these factors, along with the increasing occurrence of gastrointestinal disorders and the expansion of healthcare infrastructure in nations such as China and India. Market growth is further propelled by government initiatives and policies that support maternal and child health, making domperidone more accessible and affordable.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global domperidone market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Lupin Limited
• Novartis AG
• GlaxoSmithKline PLC
• Mankind Pharma Limited
• Merck Co., Ltd.
• SanofiAventisGroupe
• Cadila Healthcare Limited
• Abbott Laboratories
• Eli Lilly and Company
• AstraZeneca Plc
• Torrent Pharmaceuticals Ltd.
• Sun Pharmaceutical Industries Ltd,
• Pfizer In.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2023, Cadila Pharmaceuticals, a leading pharmaceutical company, announced the successful launch of 10 products. These groundbreaking additions to our portfolio offer advanced medications as solutions to address various abnormal medical conditions, which further improve the patients' care. Cadila developed Esiloc D capsules containing Esomeprazole EC and Domperidone EC to provide effective relief for gastrointestinal reflux disease (GERD).

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global domperidone market based on the below-mentioned segments:

Global Domperidone Market, By Dosage Form

• Oral Solution
• Tablets
• Injection

Global Domperidone Market, By Route of Administration

• Oral
• Intravenous

Global Domperidone Market, By Indications

• Nausea and Vomiting
• Functional Dyspepsia
• Gastric Motility Disorders

Global Domperidone Market, By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

Global Domperidone Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa